LEADER 02009nam  2200397   450 
001 9910719772503321
005 20230629191520.0
010   $a3-0365-7184-1
035   $a(CKB)4960000000467881
035   $a(NjHacI)994960000000467881
035   $a(EXLCZ)994960000000467881
100   $a20230629d2023      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGenetic and Epigenetic Regulations of Tumor Progression and Metastasis /$fBozena Smolkova, Julie Earl, Agapi Kataki, editors
210  1$a[Place of publication not identified] :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2023.
215   $a1 online resource (208 pages)
311   $a3-0365-7185-X 
330   $aGenetic aberrations and epigenetic modifications are critical drivers of cancer progression and metastasis. Although recurrent mutations in primary and metastatic cancers have been shown to be concordant, there are several metastasis-associated mutations responsible for resistance to specific therapies that are frequently located in genes that regulate DNA methylation and chromatin modifications. Recent studies have shown that distinct subgroups of poor-prognosis tumors lack genetic alterations but are epigenetically regulated, pointing to the critical role of epigenetic modifications in cancer progression. This Special Issue provides novel insights into the mechanisms underlying processes associated with cancer cell plasticity and the development of metastatic disease.
606   $aChemotherapy
606   $aTumors
615  0$aChemotherapy.
615  0$aTumors.
676   $a616.994059
702   $aEarl$b Julie
702   $aSmolkova$b Bozena
702   $aKataki$b Agapi
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910719772503321
996   $aGenetic and Epigenetic Regulations of Tumor Progression and Metastasis$93360304
997   $aUNINA